Phenaros utilizes phenomics and AI-driven cell morphological profiling to accelerate drug discovery for rare diseases by automating data collection and experimentation. The company addresses the challenge of limited high-quality data in drug development, enabling faster and more efficient identification of new and repurposed therapeutics.
Funding
Funding not disclosed
Founders
Product
Problem
Drug discovery for rare diseases is hindered by the limited availability of high-quality data, making it difficult to identify and develop effective therapeutics. Traditional methods of data collection and experimentation are often slow, expensive, and lack the depth of insight needed to understand complex disease mechanisms.
Solution
Phenaros leverages phenomics and artificial intelligence (AI) to accelerate drug discovery for rare diseases through automated cell morphological profiling. The company employs Cell Painting, a phenomics approach, to reveal detailed cellular information, which is then combined with AI modeling for iterative drug discovery. By using state-of-the-art AI to guide decisions and robotics and automation for intelligent experimentation, Phenaros systematically engineers the data used to build its AI system. This data-centric approach enables the company to perform targeted experiments, reducing both the time and cost associated with traditional drug discovery cycles.
Target Audience
Phenaros primarily targets pharmaceutical companies, research institutions, and drug development organizations focused on discovering and developing treatments for rare diseases.
Features
- Cell Painting-based phenomics for detailed cellular insights
- AI-driven analysis of cell morphology to identify potential drug candidates
- Automated data collection and experimentation using robotics
- Iterative drug discovery process guided by AI modeling
- Systematic engineering of data to optimize AI system performance